Direct answer:The NDC Directory of the FDA contains information submitted as required by Drug Listing, which may include unapproved medicines. The product has a NDC or appears in the catalogue, and does not represent FDA's approval of the product, verification of declared information or determination that it can be legally sold. Legal listing requires separate confirmation of the applicable approvals, monographs or other statutory paths.

FDA specifies that neither the NDC number nor the NDC Directory entry is an FDA approval certificate. Do not use NDC in packaging products, websites or sales materials to imply FDA approval.

Four concepts need to be separated.

  • Establishment Registration:The applicable pharmaceutical facilities are required to register information on their businesses and facilities with the FDA.
  • Drug Listing:Responsible subjects submit listing information for specific drugs for regulatory use by FDA.
  • NDC:The numbering structure used to identify listed drugs is not an approval number.
  • FDA Approval / Legal Marketing Pathway:The availability of medicines depends on whether they conform to the applicable NDA/ANDA, OTC Monograph or other regulatory pathways.

Why don't you approve the drug?

The FDA states that the data in the NDC catalogue are derived from the Drug Listing information submitted by the enterprise and that the catalogue may contain products with different approval status. FDA uses this information for regulatory control and catalogues do not amount to FDA having reviewed the safety and effectiveness of the product.

How enterprises should check the legal listing path

  1. Confirm whether the product is a pharmaceutical and the intended use, composition, formulation, labelling and sales declaration.
  2. Determines the product’s corresponding listing path and finds the relevant NDA, ANDA or OTC Monograph basis.
  3. Verify who is responsible for the registration of the manufacturing facility, U.S. agent, Labeler Code, NDC and Drug Listing, respectively.
  4. Check product records in the official FDA database, while reading the catalogue exemption statement and the statutory requirements of the path.
  5. If the product is a non-approved drug, assess whether there is an applicable legal basis for listing or the need to stop sales and consult professionals.

Do not use historical sales as automatic exemptions.

FDA follows a risk-based regulatory enforcement strategy for unapproved medicines. Certain non-authorized products may be sold under specific circumstances or are within the enforcement discretion of the FDA, but this does not constitute a general authorization for all products of the same kind. An enterprise should not assume that its products are legal solely on the basis of the sale of the bids, the NDC catalogue records or third party statements.

Official sources

Date of official data check: 2026-10-27. The legal status of unapproved medicines in individual cases needs to be judged against product facts and specific regulations.

Communication of drug regulatory pathwaysView pricing and order online ↗

Continue reading and preparation

Further consolidation of project information is availableAssessment of drug classification and regulatory pathways; The scope, processing cycles and costs are shown on the corresponding service page.